{
  "study_id": "NCT01057810",
  "study_title": "Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer",
  "table_name": "Table 1",
  "table_title": "Demographic and Baseline Patient Characteristics",
  "description": "Patient demographics and baseline disease characteristics for patients treated with ipilimumab or placebo.",
  "footnotes": [
    "Abbreviations: ECOG, Eastern Cooperative Oncology Group; IU, International Units; PSA, prostate-specific antigen; ULN, upper limit of normal."
  ],
  "groups": [
    {
      "name": "Ipilimumab",
      "n": 400,
      "type": "Intervention"
    },
    {
      "name": "Placebo",
      "n": 202,
      "type": "Placebo"
    }
  ],
  "characteristics": [
    {
      "original_label": "Median age, years (range)",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "numeric_median_iqr",
          "median": 70.0,
          "iqr_min": 44.0,
          "iqr_max": 91.0,
          "raw_string": "70 (44-91)",
          "notes": "The source table reports range, not IQR."
        },
        {
          "group_name": "Placebo",
          "data_type": "numeric_median_iqr",
          "median": 69.0,
          "iqr_min": 42.0,
          "iqr_max": 92.0,
          "raw_string": "69 (42-92)",
          "notes": "The source table reports range, not IQR."
        }
      ]
    },
    {
      "original_label": "Age-group",
      "standardized_name": "Age",
      "category": "Demographics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Age-group"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Age-group"
        }
      ]
    },
    {
      "original_label": "< 65 years",
      "standardized_name": "Age <65 years",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 26.0,
          "raw_string": "104 (26)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 32.0,
          "raw_string": "65 (32)"
        }
      ]
    },
    {
      "original_label": "≥ 65 years",
      "standardized_name": "Age >=65 years",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 296.0,
          "percentage": 74.0,
          "raw_string": "296 (74)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 137.0,
          "percentage": 68.0,
          "raw_string": "137 (68)"
        }
      ]
    },
    {
      "original_label": "Race",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Race"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Race"
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 361.0,
          "percentage": 90.0,
          "raw_string": "361 (90)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 185.0,
          "percentage": 92.0,
          "raw_string": "185 (92)"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 20.0,
          "percentage": 5.0,
          "raw_string": "20 (5)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 5.0,
          "raw_string": "11 (5)"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.0,
          "raw_string": "4 (1)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 (1)"
        }
      ]
    },
    {
      "original_label": "American Indian/Alaskan",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "raw_string": "2 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1 (< 1)",
          "notes": "Percentage is less than 1."
        }
      ]
    },
    {
      "original_label": "Native Hawaiian/Pacific Islander",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Race",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 3.0,
          "raw_string": "12 (3)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 (2)"
        }
      ]
    },
    {
      "original_label": "Region",
      "standardized_name": "Region",
      "category": "Demographics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Region"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Region"
        }
      ]
    },
    {
      "original_label": "United States/Canada",
      "standardized_name": "Region",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 136.0,
          "percentage": 34.0,
          "raw_string": "136 (34)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 70.0,
          "percentage": 35.0,
          "raw_string": "70 (35)"
        }
      ]
    },
    {
      "original_label": "Not United States/Canada",
      "standardized_name": "Region",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Region",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 264.0,
          "percentage": 66.0,
          "raw_string": "264 (66)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 132.0,
          "percentage": 65.0,
          "raw_string": "132 (65)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status",
      "standardized_name": "ECOG Performance Status",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "ECOG performance status"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "ECOG performance status"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status 0",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 299.0,
          "percentage": 75.0,
          "raw_string": "299 (75)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 151.0,
          "percentage": 75.0,
          "raw_string": "151 (75)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status 1",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 100.0,
          "percentage": 25.0,
          "raw_string": "100 (25)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 51.0,
          "percentage": 25.0,
          "raw_string": "51 (25)"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status 2",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Lactate dehydrogenase level",
      "standardized_name": "Lactate Dehydrogenase Level",
      "category": "Lab Value",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Lactate dehydrogenase level"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Lactate dehydrogenase level"
        }
      ]
    },
    {
      "original_label": "< 200 IU/L",
      "standardized_name": "Lactate Dehydrogenase Level",
      "unit": "IU/L",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lactate Dehydrogenase Level",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 250.0,
          "percentage": 63.0,
          "raw_string": "250 (63)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 130.0,
          "percentage": 64.0,
          "raw_string": "130 (64)"
        }
      ]
    },
    {
      "original_label": "≥ 200 IU/L",
      "standardized_name": "Lactate Dehydrogenase Level",
      "unit": "IU/L",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lactate Dehydrogenase Level",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 149.0,
          "percentage": 37.0,
          "raw_string": "149 (37)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 36.0,
          "raw_string": "72(36)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Lactate Dehydrogenase Level",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Lactate Dehydrogenase Level",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Hemoglobin concentration",
      "standardized_name": "Hemoglobin Concentration",
      "category": "Lab Value",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Hemoglobin concentration"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Hemoglobin concentration"
        }
      ]
    },
    {
      "original_label": "< 11 g/dL",
      "standardized_name": "Hemoglobin Concentration",
      "unit": "g/dL",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Hemoglobin Concentration",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 8.0,
          "raw_string": "31 (8)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 7.0,
          "raw_string": "14 (7)"
        }
      ]
    },
    {
      "original_label": "≥ 11 g/dL",
      "standardized_name": "Hemoglobin Concentration",
      "unit": "g/dL",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Hemoglobin Concentration",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 364.0,
          "percentage": 91.0,
          "raw_string": "364 (91)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 183.0,
          "percentage": 91.0,
          "raw_string": "183 (91)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Hemoglobin Concentration",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Hemoglobin Concentration",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 1.0,
          "raw_string": "5 (1)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.0,
          "raw_string": "5 (3)"
        }
      ]
    },
    {
      "original_label": "Measurable disease",
      "standardized_name": "Measurable Disease",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Measurable disease"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Measurable disease"
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Measurable Disease",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Measurable Disease",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 169.0,
          "percentage": 42.0,
          "raw_string": "169 (42)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 48.0,
          "raw_string": "96 (48)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Measurable Disease",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Measurable Disease",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 228.0,
          "percentage": 57.0,
          "raw_string": "228 (57)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 51.0,
          "raw_string": "102 (51)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Measurable Disease",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Measurable Disease",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "raw_string": "3 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.0,
          "raw_string": "4 (2)"
        }
      ]
    },
    {
      "original_label": "Alkaline phosphatase level",
      "standardized_name": "Alkaline Phosphatase Level",
      "category": "Lab Value",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Alkaline phosphatase level"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Alkaline phosphatase level"
        }
      ]
    },
    {
      "original_label": "< 1.5 × ULN",
      "standardized_name": "Alkaline Phosphatase Level",
      "unit": "× ULN",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Alkaline Phosphatase Level",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 327.0,
          "percentage": 82.0,
          "raw_string": "327 (82)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 176.0,
          "percentage": 87.0,
          "raw_string": "176 (87)"
        }
      ]
    },
    {
      "original_label": "≥ 1.5 × ULN",
      "standardized_name": "Alkaline Phosphatase Level",
      "unit": "× ULN",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Alkaline Phosphatase Level",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 18.0,
          "raw_string": "72 (18)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 13.0,
          "raw_string": "26 (13)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Alkaline Phosphatase Level",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Alkaline Phosphatase Level",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "raw_string": "1 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0"
        }
      ]
    },
    {
      "original_label": "Gleason score",
      "standardized_name": "Gleason Score",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Gleason score"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Gleason score"
        }
      ]
    },
    {
      "original_label": "≤ 7",
      "standardized_name": "Gleason Score <=7",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Gleason Score",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 189.0,
          "percentage": 47.0,
          "raw_string": "189 (47)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 103.0,
          "percentage": 51.0,
          "raw_string": "103 (51)"
        }
      ]
    },
    {
      "original_label": "≥ 8",
      "standardized_name": "Gleason Score >=8",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Gleason Score",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 192.0,
          "percentage": 48.0,
          "raw_string": "192 (48)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 91.0,
          "percentage": 45.0,
          "raw_string": "91 (45)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Gleason Score",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Gleason Score",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 19.0,
          "percentage": 5.0,
          "raw_string": "19 (5)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 4.0,
          "raw_string": "8 (4)"
        }
      ]
    },
    {
      "original_label": "PSA",
      "standardized_name": "Prostate-Specific Antigen",
      "category": "Lab Value",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "PSA"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "PSA"
        }
      ]
    },
    {
      "original_label": "Median (range), µg/L",
      "standardized_name": "Prostate-Specific Antigen",
      "unit": "µg/L",
      "category": "Lab Value",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prostate-Specific Antigen",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "numeric_median_iqr",
          "median": 41.2,
          "iqr_min": 0.05,
          "iqr_max": 4956.0,
          "raw_string": "41.2 (0.05-4,956)",
          "n_for_value": 393
        },
        {
          "group_name": "Placebo",
          "data_type": "numeric_median_iqr",
          "median": 49.5,
          "iqr_min": 0.01,
          "iqr_max": 9297.0,
          "raw_string": "49.5 (0.01-9,297)",
          "n_for_value": 197
        }
      ]
    },
    {
      "original_label": "Bone metastases",
      "standardized_name": "Bone Metastases",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Bone metastases"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Bone metastases"
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Bone Metastases",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Bone Metastases",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 312.0,
          "percentage": 78.0,
          "raw_string": "312 (78)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 159.0,
          "percentage": 79.0,
          "raw_string": "159 (79)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Bone Metastases",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Bone Metastases",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 85.0,
          "percentage": 21.0,
          "raw_string": "85 (21)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 19.0,
          "raw_string": "39 (19)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Bone Metastases",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Bone Metastases",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "raw_string": "3 (< 1)",
          "notes": "Percentage is less than 1."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.0,
          "raw_string": "4 (2)"
        }
      ]
    },
    {
      "original_label": "Average daily worst bone pain intensity score",
      "standardized_name": "Average Daily Worst Bone Pain Intensity Score",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Average daily worst bone pain intensity score"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Average daily worst bone pain intensity score"
        }
      ]
    },
    {
      "original_label": "None",
      "standardized_name": "Average Daily Worst Bone Pain Intensity Score",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Average Daily Worst Bone Pain Intensity Score",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 215.0,
          "percentage": 54.0,
          "raw_string": "215 (54)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 109.0,
          "percentage": 54.0,
          "raw_string": "109 (54)"
        }
      ]
    },
    {
      "original_label": "Minimal",
      "standardized_name": "Average Daily Worst Bone Pain Intensity Score",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Average Daily Worst Bone Pain Intensity Score",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 179.0,
          "percentage": 45.0,
          "raw_string": "179 (45)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 90.0,
          "percentage": 45.0,
          "raw_string": "90 (45)"
        }
      ]
    },
    {
      "original_label": "Not reported",
      "standardized_name": "Average Daily Worst Bone Pain Intensity Score",
      "category": "Clinical Characteristic",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Average Daily Worst Bone Pain Intensity Score",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "raw_string": "6 (< 2)",
          "notes": "Percentage is less than 2."
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 (2)"
        }
      ]
    },
    {
      "original_label": "Bisphosphonate use",
      "standardized_name": "Bisphosphonate Use",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "header",
          "raw_string": "Bisphosphonate use"
        },
        {
          "group_name": "Placebo",
          "data_type": "header",
          "raw_string": "Bisphosphonate use"
        }
      ]
    },
    {
      "original_label": "Yes",
      "standardized_name": "Bisphosphonate Use",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Bisphosphonate Use",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 99.0,
          "percentage": 25.0,
          "raw_string": "99 (25)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 62.0,
          "percentage": 31.0,
          "raw_string": "62 (31)"
        }
      ]
    },
    {
      "original_label": "No",
      "standardized_name": "Bisphosphonate Use",
      "category": "Prior Treatment",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Bisphosphonate Use",
      "group_data": [
        {
          "group_name": "Ipilimumab",
          "data_type": "categorical_count_percentage",
          "count": 301.0,
          "percentage": 75.0,
          "raw_string": "301 (75)"
        },
        {
          "group_name": "Placebo",
          "data_type": "categorical_count_percentage",
          "count": 140.0,
          "percentage": 69.0,
          "raw_string": "140 (69)"
        }
      ]
    }
  ]
}